METAP2 inhibitors and methods of treating obesity

Inventors

Petersen, John S. • Shanahan, James

Assignees

SynDevRX Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9750737-B2

Patent

Publication Date

2017-09-05

Expiration Date


Abstract

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

Core Innovation

The disclosed invention relates to methods for improving or restoring leptin sensitivity in a subject in need thereof by administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof. Disclosed embodiments comprise polymer-peptide-fumagillol conjugates, including HPMA-based polymers bearing peptide linkers, acting as methionine aminopeptidase-2 inhibitor conjugates. A cleavable or self-immolating linker links the inhibitor moiety to release active derivatives in target tissue, improving delivery and reducing cellular efflux.

The disclosure identifies these conjugates for use in weight loss and obesity-related therapy. Recited compounds encompass fumagillin and fumagillol derivatives defined by specified groups or structural formulas with defined peptide sequences, linkers, and inhibitor moieties. In diet-induced obesity studies, the compounds produce dose-responsive reductions in body weight and fat, reduce food consumption, and improve metabolic measures. Because the background section is omitted from the provided content, the specific problem articulated in that section is not explicitly described.

Claims Coverage

The claims include two independent claims directed to methods for improving or restoring leptin sensitivity in a subject in need thereof, comprising two inventive features.

Administration of compounds from a specified group

An independent claim covers administering to a subject in need thereof a therapeutically effective amount of at least one compound selected from a specified group, or a pharmaceutically acceptable salt thereof, to improve or restore leptin sensitivity.

Administration of formula-defined compounds

An independent claim covers administering to a subject in need thereof a therapeutically effective amount of at least one compound of a recited structural formula, or a pharmaceutically acceptable salt thereof, comprising defined peptide, linker, and methionine aminopeptidase-2 inhibitor or alkyl components, to improve or restore leptin sensitivity.

The independent claims cover two compound-defined administration methods to improve or restore leptin sensitivity in a subject in need thereof, utilizing either compounds selected from a specified group or compounds defined by a structural formula reciting defined peptide, linker, and inhibitor components.

Stated Advantages

The conjugates are stated to provide an improved therapeutic index compared with unconjugated compounds, achieving greater weight loss at substantially lower exposure and with less frequent dosing.

The conjugates are stated to provide improved water solubility, stability, longer half-life, greater potency, and reduced neurotoxicity compared with known fumagillin derivatives.

The approach is stated to improve delivery, pharmacokinetic properties, duration of delivery, and reduce cellular efflux via a cleavable-linker design.

The compounds are stated to improve or restore leptin sensitivity, produce dose-responsive reductions in body weight and fat, decrease food consumption, and decrease a subject's body weight by about 1% to about 50%.

The compounds are stated to address cardiometabolic risk factors and improve metabolic measures, including glucose, insulin, leptin, plasma triglyceride levels, LDL-cholesterol levels, C-reactive protein levels, and systolic and diastolic blood pressure.

Documented Applications

Improving or restoring leptin sensitivity in a subject in need thereof.

Inducing weight loss and treating obesity, metabolic syndrome, and related conditions using methionine aminopeptidase-2 inhibitor conjugates or modified fumagillol compounds.

Improving insulin sensitivity and glycemic control.

Experimental evaluations in diet-induced-obesity rats and mice documenting weight loss, reduced food intake, and metabolic outcomes with Compound 16.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.